Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhelion Life SciencesSTU:4YX0 PEG Ratio is 0.00 as of Aug. 07, 2026. The stock has 3 warning signs investors should review. Among 349 Drug Manufacturers companies, Rhelion Life Sciences ranks worse than 66.19% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Rhelion Life Sciences's PEG Ratio or its related term are showing as below:
STU:4YX0'
s PEG Ratio Range Over the Past 10 Years
Min: 0.35 Med: 0.88 Max: 6.56
Current: 2.86
During the past 8 years, Rhelion Life Sciences's highest PEG Ratio was 6.56. The lowest was 0.35. And the median was 0.88.
STU:4YX0's PEG Ratio is ranked worse than 66.19% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.8
vs STU:4YX0: 2.86
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Rhelion Life Sciences (STU:4YX0) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhelion Life Sciences PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Rhelion Life Sciences's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Rhelion Life Sciences (STU:4YX0) has a PEG Ratio of 0.00 as of Aug. 07, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Rhelion Life Sciences and its competitors. Over the past decade, Rhelion Life Sciences' PEG Ratio has ranged from 0.35 to 6.56. According to the industry distribution chart, Rhelion Life Sciences ranks #231 out of 349 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is Rhelion Life Sciences' PEG Ratio too high?
Rhelion Life Sciences' current PEG Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 6.56. Based on the distribution chart, Rhelion Life Sciences ranks #231 out of 349 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Rhelion Life Sciences' PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Rhelion Life Sciences ranks #231 out of 349 companies for PEG Ratio. This places Rhelion Life Sciences in the lower half of its industry. The industry median PEG Ratio is 1.80. Historically, Rhelion Life Sciences' own PEG Ratio has ranged from 0.35 to 6.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.80, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Rhelion Life Sciences and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhelion Life Sciences's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (STU:4YX0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current PEG Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Rhelion Life Sciences (STU:4YX0), the current PEG Ratio is 0.00 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YX0 has been successfully added to your 
